புற்றுநோய் மருத்துவ பரிசோதனைகளின் இதழ்

Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Focused Therapeutic Strategies for the Most Lethal Cancer

Abstract

David Milar

Pancreatic Ductal Adenocarcinoma is among the most lethal cancers, characterized by limited treatment options and poor prognosis. Its hallmark resistance to conventional therapies necessitates the exploration of targeted therapeutic approaches. Recent advances have significantly deepened our understanding of the oncogenic pathways driving PDAC development and progression. This article reviews clinical and preclinical strategies targeting these pathways, highlighting promising avenues for treating this deadly cancer.